Employment: Director, Global Regulatory Strategist, Bristol-Myers Squibb
Employment Sector: Industry
Kristina D. Chadwick, Ph.D., DABT, recently transitioned to Global Regulatory Affairs at Bristol-Myers Squibb (BMS) where she drives drug development regulatory strategy and health authority interactions. Previously she was a Director and Therapy Area Head for Fibrotic and Metabolic Diseases in Drug Safety Evaluation (nonclinical toxicology) at BMS. She received her PhD in Pharmacology and Toxicology and Duke University with a dissertation on neurodevelopmental toxicity of a pesticide, chlorpyrifos. She continued her research with pesticides at the University of Washington in Seattle after graduation. Kristina joined the pharmaceutical industry at Targeted Genetics, the Roche Palo Alto, before joining BMS in 2005. During her tenure, she’s supported IND/CTAs, global marketing applications (NDA/MAA), life-cycle management activities, and has authored numerous peer-reviewed publications. Kristina is a Full Member of the Society of Toxicology (SOT), American College of Toxicology, and is a Diplomate of the American Board of Toxicology. She is an active member of SOT, previously serving on the Membership Committee 2016-19 (Co-Chair then Chair 2017-19), the Executive Council of the Women in Toxicology Special Interest Group (Secretary-Treasurer 2002-04, Councilor 2007-09, Presidential Chain 2010-14), and as VP-elect for the Regulatory and Safety Evaluation Specialty Section (2020-21).
